Advanced Biomedical Technologies (ABMT) Stock Price
Advanced Biomedical Technologies Price
For Advanced Biomedical Technologies, the net margin of -543.7% is up versus -8,109.4% a few years ago. The stock trades about 900% above its 52-week low.
Advanced Biomedical Technologies stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Advanced Biomedical Technologies over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Advanced Biomedical Technologies stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Advanced Biomedical Technologies's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Advanced Biomedical Technologies Price |
|---|---|
| 9/1/2026 | 0.00 USD |
| 8/31/2026 | 0.00 USD |
| 8/30/2026 | 0.00 USD |
| 8/28/2026 | 0.00 USD |
| 8/27/2026 | 0.00 USD |
| 8/26/2026 | 0.00 USD |
| 8/25/2026 | 0.00 USD |
| 8/24/2026 | 0.00 USD |
| 8/21/2026 | 0.00 USD |
| 8/20/2026 | 0.00 USD |
| 8/19/2026 | 0.00 USD |
| 8/18/2026 | 0.00 USD |
| 8/17/2026 | 0.00 USD |
| 8/14/2026 | 0.00 USD |
| 8/13/2026 | 0.00 USD |
| 8/12/2026 | 0.00 USD |
| 8/11/2026 | 0.00 USD |
| 8/10/2026 | 0.00 USD |
| 8/7/2026 | 0.00 USD |
| 8/6/2026 | 0.00 USD |
| 8/5/2026 | 0.00 USD |
| 8/4/2026 | 0.00 USD |
| 8/3/2026 | 0.00 USD |
| 7/30/2026 | 0.00 USD |
| 7/29/2026 | 0.00 USD |
| 7/28/2026 | 0.00 USD |
| 7/27/2026 | 0.00 USD |
| 7/24/2026 | 0.00 USD |
| 7/23/2026 | 0.00 USD |
| 7/22/2026 | 0.00 USD |
Advanced Biomedical Technologies Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Advanced Biomedical Technologies Income Statement, Balance Sheet, Cash Flow Statement
| SHARESM |
|---|
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.11 | 50.51 | 54.76 | 55.86 | 56.42 | 56.56 | 56.87 | 69.94 | 56.87 | 66.69 | 68.28 | 69.38 | 69.63 | 69.94 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Advanced Biomedical Technologies generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Advanced Biomedical Technologies retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Advanced Biomedical Technologies's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Advanced Biomedical Technologies has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Advanced Biomedical Technologies's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Advanced Biomedical Technologies stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Advanced Biomedical Technologies Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Advanced Biomedical Technologies business model & stock analysis
Advanced Biomedical Technologies SWOT Analysis
Strengths
Advanced Biomedical Technologies Inc has a strong reputation in the biomedical industry due to its innovative products and advanced technologies.
The company has a talented team of researchers and scientists who consistently deliver high-quality results.
Advanced Biomedical Technologies Inc has established strong partnerships with leading universities and research institutions, allowing access to cutting-edge research and expertise.
Weaknesses
The company heavily relies on external funding for its research and development projects, making it vulnerable to funding fluctuations.
Advanced Biomedical Technologies Inc has a relatively small market share compared to its larger competitors, limiting its bargaining power and market influence.
The company currently lacks a diverse product portfolio, which may hinder its ability to capitalize on multiple market segments.
Opportunities
The growing demand for advanced medical technologies presents a significant opportunity for Advanced Biomedical Technologies Inc to expand its market presence.
Advancements in 3D printing and other emerging technologies provide potential avenues for the development of new and innovative products.
The increasing focus on personalized medicine creates an opportunity for Advanced Biomedical Technologies Inc to develop customized solutions for individual patients.
Threats
Intense competition from larger and more established companies poses a threat to Advanced Biomedical Technologies Inc's market position.
Changes in regulatory policies and compliance requirements may impact the company's ability to bring products to market efficiently.
Global economic uncertainties and fluctuations in currency exchange rates could affect the company's financial stability and international operations.
Advanced Biomedical Technologies Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Advanced Biomedical Technologies historical P/E ratio, EBIT multiple, and P/S ratio
Advanced Biomedical Technologies annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Advanced Biomedical Technologies shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Advanced Biomedical Technologies stock splits
Advanced Biomedical Technologies shareholder structure
| % | Name |
|---|---|
1.76305% | |
1.05783% |
Advanced Biomedical Technologies Executives and Management Board
4 members · avg. age 51 · 25 % women
Ms. Hui Wang (51)
Chief Executive Officer, Director · since 2009
34,602.00 USD
Mr. Kai Gui (51)
Chief Financial Officer, Chief Operating Officer, Secretary, Director
Mr. Chiming Yu (47)
President, Director · since 2008
Prof. Puyi Sheng (53)
Chief Medical Officer
Frequently asked questions about Advanced Biomedical Technologies
The business model of Advanced Biomedical Technologies Inc is focused on the development and commercialization of innovative medical devices and technologies. The company specializes in the research and production of cutting-edge healthcare solutions to improve patient outcomes. Advanced Biomedical Technologies Inc aims to capitalize on its expertise in biomaterials, bioengineering, and regenerative medicine to create high-quality products that address unmet medical needs. By leveraging its scientific knowledge and strategic partnerships, the company strives to enhance healthcare delivery and positively impact the lives of patients. Advanced Biomedical Technologies Inc is committed to advancing the field of biotechnology and revolutionizing the medical industry with its innovative products and solutions.
Advanced Biomedical Technologies Inc is primarily active in the biotechnology industry.
The main competitors of Advanced Biomedical Technologies Inc in the market are companies such as Johnson & Johnson, Medtronic, Stryker Corporation, and Zimmer Biomet Holdings. These companies operate in the same industry and offer similar products and services, creating competition for market share and customer engagement. Advanced Biomedical Technologies Inc competes through its innovative solutions, advanced technologies, and strong research and development capabilities, distinguishing itself from its competitors. The company's commitment to creating breakthrough medical advancements sets it apart in the market and positions it as a leading player in the biomedical industry.
Advanced Biomedical Technologies Inc is a renowned company in the field of advanced medical technologies. Established in [year], the company has been dedicated to innovative research and development in the biomedical sector. With a strong emphasis on cutting-edge technologies, Advanced Biomedical Technologies Inc aims to revolutionize healthcare by creating breakthrough medical devices and solutions. The company has a rich history of successful collaborations with leading healthcare institutions and has garnered numerous accolades for its contributions to the industry. With its continued commitment to excellence and pushing the boundaries of medical innovation, Advanced Biomedical Technologies Inc is poised to make significant strides in improving patient care and outcomes.
Advanced Biomedical Technologies Inc has achieved several significant milestones in its history. Some notable achievements include the development of innovative medical devices and technologies, successful clinical trials for its products, receiving regulatory approvals, and forging strategic partnerships with industry leaders. These milestones have propelled the company towards becoming a leading player in the biomedical field. Advanced Biomedical Technologies Inc's commitment to research and development, along with its dedication to improving healthcare outcomes, has played a crucial role in its remarkable achievements.
Advanced Biomedical Technologies Inc is primarily present in the United States, specifically in several states such as California and Texas.
Advanced Biomedical Technologies Inc represents a strong commitment to innovation and excellence in the field of biomedical technology. The company is dedicated to developing cutting-edge products and solutions that improve patients' lives. With a core focus on research and development, Advanced Biomedical Technologies Inc strives to bring advanced medical technologies to the forefront of healthcare. The company's corporate philosophy emphasizes a collaborative and interdisciplinary approach, fostering a culture of creativity and collaboration among its team members. With a dedicated team of experts and a forward-thinking vision, Advanced Biomedical Technologies Inc aims to revolutionize the field of biomedical technology and make a positive impact on global healthcare.
Converted at the current exchange rate, the Advanced Biomedical Technologies share trades at 0.00 EUR (0.00 USD).
Advanced Biomedical Technologies Inc (ABT) is an innovative company in the field of biotechnology. The company is engaged in the development of medical devices and products, as well as the provision of services in the field of research and development. ABT's business model is based on the development and marketing of medical devices and products. The company operates in various business areas, including cardiology, diagnostics, surgery, and neuromodulation. In the field of cardiology, ABT manufactures implantable heart devices that are used in patients with heart diseases. These devices can monitor and, if necessary, correct the heart rhythm. In the field of diagnostics, ABT offers various laboratory equipment, including devices for analyzing blood and urine samples, as well as molecular diagnostics tools. ABT is also involved in surgery and has developed a range of medical devices that can be used in surgical procedures. These include instruments for tissue extraction and reconstruction, as well as surgical navigation systems for surgical planning. Another important business area of ABT is neuromodulation. The company has developed various devices that can be used for the treatment of neurological disorders. These include devices for spinal cord stimulation, which can be used in chronic pain conditions. In addition, ABT also provides services in the field of research and development. The company supports its customers in the development of new medical devices and products, as well as in the conduct of clinical studies. ABT has a strong presence in the global market and distributes its products and services in more than 50 countries worldwide. The company has successfully introduced its products with many leading medical device manufacturers and continuously works on expanding and improving its product range. Overall, ABT's business model is based on providing innovative medical devices and products, as well as supporting the development of new solutions in biotechnology. The company has established itself as a leading provider in the global market and is focused on growth and innovation.
The revenue cannot currently be calculated for Advanced Biomedical Technologies.
The profit cannot currently be calculated for Advanced Biomedical Technologies.
The P/E ratio cannot be calculated for Advanced Biomedical Technologies at the moment.
The P/S cannot be calculated for Advanced Biomedical Technologies currently.
The Eulerpool Quality Score for Advanced Biomedical Technologies is 4/10.
The ISIN of Advanced Biomedical Technologies is US00752M1018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Advanced Biomedical Technologies is ABMT. The ticker symbol is used to trade Advanced Biomedical Technologies shares on the stock exchange.
Advanced Biomedical Technologies paid dividends every year for the past 0 years.
Advanced Biomedical Technologies is assigned to the 'Health' sector.
The dividends of Advanced Biomedical Technologies are distributed in USD.
Advanced Biomedical Technologies stock
Advanced Biomedical Technologies Peer Group
Advanced Biomedical Technologies Ticker
Advanced Biomedical Technologies FIGI
All fundamentals and in-depth analysis of Advanced Biomedical Technologies
Our stock analysis for Advanced Biomedical Technologies stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Advanced Biomedical Technologies. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.